Vall D'hebron Institut De Recerca

Running trials

• Active, not recruiting

  A Long-term Study to Monitor the Health Status of People With Cystic Fibrosis Who Took Part in a Previous Study With BI 3720931 (Lenticlair™-ON)

  NCT06962852· Phase 1/2· Source

• Recruiting

  A multicenter, open label, two cohort, single arm, phase II study to evaluate the efficacy and safety of the anti-TROP2 antibody-drug conjugate sacituzumab govitecan in patients with advanced differentiated and anaplastic thyroid neoplasms.

  2023-504898-20-00· Phase 2· Source

• Recruiting

  Clinical trial of trabectedin, irinotecann and low-dose radiation therapy in advanced/metastatic sarcomas.

  NCT05131386· Phase 2· Source

• Active, not recruiting

  A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors

  NCT06157892· Phase 2· Source

• Recruiting

  A multicentric, randomized, double-blind, placebo-controlled trial to evaluate the efficacy of COLIRIOBCN070660 administered topically in patients with moderately severe to severe non-proliferative diabetic retinopathy

  2023-505791-30-01· Phase 2/3· Source

• Recruiting

  A PHASE I STUDY OF THE CEACAM5 x CD3 ANTIBODY NILK-2301 IN COLORECTAL CANCER

  2023-508058-24-01· Phase 1· Source

• Active, not recruiting

  A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer.

  NCT06206837· Phase 1/2· Source

• Recruiting

  A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma

  NCT06064877· Phase 3· Source

• Recruiting

  A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

  NCT06136559· Phase 3· Source

• Active, not recruiting

  A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2

  NCT06003231· Phase 2· Source

• Recruiting

  Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement

  NCT05727176· Phase 2· Source

• Recruiting

  Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia

  NCT05327894· Phase 3· Source

• Recruiting

  Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment

  NCT05363280· Phase 2· Source

• Active, not recruiting

  Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC

  NCT05301842· Phase 3· Source

• Active, not recruiting

  A Research Study on How Well Concizumab Works for You if You Have Haemophilia A or B With or Without Inhibitors

  NCT05135559· Phase 3· Source

• Active, not recruiting

  Lorlatinib Continuation Study

  NCT05144997· Phase 4· Source

• Active, not recruiting

  A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)

  NCT04895696· Phase 2· Source

• Recruiting

  An international trial for children with atypical teratoid/rhabdoid tumours (ATRT)

  2022-501456-28-00· Phase 3· Source

• Active, not recruiting

  A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer

  NCT03873402· Phase 3· Source

• Active, not recruiting

  Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib

  NCT03235245· Phase 2· Source

• Active, not recruiting

  A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma

  NCT03470922· Phase 2/3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers3 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• Chronic lymphocytic leukaemia1 recruiting
• Colorectal cancer1 recruiting
• Diabetic eye disease1 recruiting
• Haemophilia1 recruiting
• Head and neck cancer1 recruiting
• Sarcoma1 recruiting
• Thyroid cancer1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  Optimizing Albuminuria Treatment in CKD With Finerenone and Semaglutide

  NCT07819227· Phase 2· Source

• Completed

  A study to test how well BI 3720931 is tolerated and whether it improves lung function in people with cystic fibrosis (LenticlairTM 1)

  2023-503281-23-00· Phase 1/2· Source

• Completed

  NXP800 in subjects with Ovarian Cancer

  NCT05226507· Phase 1· Source

• Completed

  RANDOMIZED, CONTROLLED, OPEN, MULTICENTRIC CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A COMBINATION OF ANTI-TUBERCULOUS DRUGS BASED ON HIGH DOSE RIFAMPICIN, HIGH DOSE MOXIFLOXACIN AND LINEZOLID IN PATIENTS WITH BACILLIFEROUS PULMONARY TUBERCULOSIS (RML-TB).

  2023-509075-17-00· Phase 2· Source

• Completed

  Study of BMS-986466 with Adagrasib with or without Cetuximab in Participants with KRAS G12C-mutant Solid Tumors

  NCT06024174· Phase 1/2· Source

• Completed

  A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor

  NCT06065540· Phase 3· Source

• Completed

  A Phase 2 Study of the Effects of Ponsegromab on Health-Related Quality of Life and Safety in Patients With Heart Failure (GARDEN-TIMI 74)

  NCT05492500· Phase 2· Source

• Completed

  A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Assess the Efficacy, Safety, Tolerability, PK, and Biomarker Effects of PTC857 in Adult Subjects With Amyotrophic Lateral Sclerosis (CARDINALS)

  NCT05349721· Phase 2· Source

• Completed

  Study of Nab-Paclitaxel and Gemcitabine and Plus/Minus VCN-01 in Patients With Metastatic Pancreatic Cancer

  NCT05673811· Phase 2· Source

• Completed

  Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder

  NCT05512377· Phase 2· Source

• Active, not recruiting

  Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations

  NCT05544552· Phase 1/2· Source

• Completed

  Adjusted Brodalumab Dose Compared With Standard Brodalumab Dose in Subjects With Moderate-to-severe Plaque Psoriasis and ≥120 kg Body Weight

  NCT04306315· Phase 4· Source

• Completed

  Phase II trial of Pembrolizumab and Olaparib in homologous-recombination deficient (HRD) advanced colorectal cancer (CRC).

  NCT05201612· Phase 2· Source

• Completed

  An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers

  2023-508954-25-00· Phase 1/2· Source

• Active, not recruiting

  New Clinical End-points in patients with primary Sjögren’s Syndrome: an Interventional Trial based on stratifYing patients

  NCT05113004· Phase 2· Source

• Completed

  A Study to Evaluate Safety, Pharmacokinetics, and Preliminary Clinical Activity of RO7276389 Alone and in Combination with Cobimetinib in Participants with BRAF-V600 Mutation-Positive Advanced Solid Tumor or BRAF-V600 Mutation-Positive Melanoma with Central Nervous System Metastases

  2023-506310-43-00· Phase 1· Source

• Completed

  Adjuvant Immunotherapy with Nivolumab + Relatlimab Fixed-dose Combination versus Nivolumab Monotherapy after Complete Resection of Stage III-IV Melanoma

  NCT05002569· Phase 3· Source

• Completed

  Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH)

  NCT05016882· Phase 2· Source

• Completed

  Pembrolizumab Plus Lenvatinib in Combination with Belzutifan in Solid Tumors

  2023-503905-12-00· Phase 2· Source

• Completed

  Proof-of-concept Study for SAR445088 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

  NCT04658472· Phase 2· Source

• Completed

  Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61)

  NCT04704219· Phase 2· Source

• Completed

  An open-label Phase 1 study of NEO-PTC-01 in patients with advanced or metastatic melanoma

  NCT04625205· Phase 1· Source

• Completed

  Study to Evaluate the Effect of Metformin in the Prevention of HG in HR[+]/HER2[-] PIK3CA-mut Advanced BC Patients

  NCT04300790· Phase 2· Source

• Completed

  ERN-EuroBloodNet Registry on Patients With Rare Red Blood Cell Defects and COVID-19

  NCT06831799· Source

• Active, not recruiting

  A Multi-Center Expanded Access Program (EAP) for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors with Rearranged During Transfection (RET) Activation (LIBRETTO-201)

  NCT03906331· Phase 4· Source

• Active, not recruiting

  Study of Two Doses of Crizanlizumab Versus Placebo in Adolescent and Adult Sickle Cell Disease Patients

  NCT03814746· Phase 3· Source

• Completed

  The Late Presenter Treatment Optimisation Study

  NCT03696160· Phase 3· Source

• Completed

  Risk Factors and Outcomes of Ischemic Stroke Associated With Tandem or Isolated Cervical Artery Occlusion in Anterior and Posterior Circulation

  NCT06965036· Source

• Completed

  A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

  NCT03141177· Phase 3· Source

• Completed

  A Randomized Controlled Trial of TNK-tPA Versus Standard of Care for Minor Ischemic Stroke With Proven Occlusion

  NCT02398656· Phase 3· Source

• Completed

  Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)

  NCT02231749· Phase 3· Source

• Completed

  An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors

  NCT01968109· Phase 1/2· Source